HC Wainwright & Co. Maintains Buy on Genmab, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Genmab (NASDAQ:GMAB) and kept the price target at $50.
March 27, 2024 | 10:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Genmab with a $50 price target.
The maintenance of a Buy rating and a $50 price target by a reputable analyst firm like HC Wainwright & Co. suggests a positive outlook on Genmab's stock. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100